# LB1 Per-Sample Score: wearable-device/min/05_go-to-market-user-experience-and-sustainability

**Date:** 2026-05-04
**Sample ID:** wearable-device_min_05_go-to-market-user-experience-and-sustainability
**Effort:** min
**Prompt under test:** idea-symphony/prompts/phase4_summary-only_min-effort.md
**Through-line count in BL1 ledger:** 18

---

## Axis A

| BL1 TL ID | TL summary | Status | Notes |
|---|---|---|---|
| TL-1 [recurring] | Limitation disclosure as feature; smoke-alarm analogy | V/P | Action 1 + Theme "Honesty Architecture": smoke-alarm analogy + 90-second cardiologist video preserved verbatim |
| TL-2 [single] | 14-day silent baseline before alerts | V/P | Action 2: "14-day silent baseline … 'here's your normal' summary screen" |
| TL-3 [recurring] | Layered alert explanation + always-include action | V/P | Action 3 + Opportunities; honest false-positive rate disclosure preserved |
| TL-4 [recurring] | Three-zone confidence indicator vs binary | V/P | Action 3 explicit; "retire any binary 'detected/not detected' framing" |
| TL-5 [recurring] | Cardiologist co-branding institutional affiliation | V/P | Action 6: "Alert thresholds developed with cardiologists at [Partner Institution]" |
| TL-6 [single] | Three-tier escalation ladder + 5-min cancel window | V/P | Action 4: tiers, 10-min follow-up, 5-min cancel window all preserved |
| TL-7 [recurring] | A/B test framing/timing on edge-confidence (0.55–0.70) only | V/P | Trade-offs: "alert copy and timing on edge-confidence events (0.55–0.70 confidence)" |
| TL-8 [recurring] | Simulated demo-event onboarding walkthrough | V/P | Action 4: "simulated demo-event walkthrough during setup" |
| TL-9 [single] | Passive behavioral observability vs A/B (6-month logs) | V/P | Action 5: named events `alert_fired`, `alert_dismissed`, etc. — exceeds BL1 specificity |
| TL-10 [single] | Tiered subscription on retention; alerts always free | V/P | Action 7: $9.99/mo History+, 12-mo retention, alerts free |
| TL-11 [recurring] | B2B clinical dashboard SaaS as defensible moat | V/P | Action 8: $200–$500/seat, Epic/Cerner integration, 2-3 reference accounts |
| TL-12 [recurring] | Opt-in research licensing + data dividend + Advisory Board | V/P | Risks bullet: $250K–$2M, Data Advisory Board, opt-in consent |
| TL-13 [recurring] | Privacy-as-product-feature (auditable architecture) | V/P | Opportunities: "iSEC Partners or Trail of Bits", "Privacy Proof screen", post-23andMe segment |
| TL-14 [single] | $49 on-demand clinical interpretation service | V/P | Opportunities: "$49 physician interpretation service" preserved |
| TL-15 [recurring] | Single deep health-system partnership > broad consumer | V/P | Opportunities: "prescribed by [Major Health System] cardiologists" |
| TL-16 [single] | Peer-reviewed validation study / ROC curve | V/P | Action 7: "IRB-approved validation study (target: 50+ patients, Holter monitor gold standard) … ROC curve" |
| TL-17 [single] | Hardware diff on sensor quality + form factor for 40+ | Dropped | No mention of comfort/battery/social-awkwardness, 20 interviews, 7-day battery, medical-aesthetic form factor in body. Trade-offs has form-factor mention but lacks the abandonment-cause finding |
| TL-18 [single] | License on-device ML to OEMs as platform play | V/P | Action 9: "ML model licensing strategic track … cardiac monitor OEMs or remote patient monitoring companies" |

**Survival rate:** 17/18 = 94.4%
**`[recurring]` survival:** 10/10 = 100% (target 100% — met)
**Verdict:** pass

## Axis B — n/a (min)

## Axis C

- Section present: Y ("Conspicuous absences" subsection in Key Considerations)
- BL1 candidates: (1) no consumer GTM/customer-acquisition channel for first 10K units; (2) no FDA regulatory pathway/timing as constraint on GTM sequence; (3) no churn/long-term-engagement after 14-day baseline
- Output absences: (1) pricing sensitivity / willingness-to-pay evidence for $9.99 and $49; (2) international regulatory pathways (CE/MDR/Health Canada); (3) churn and retention mechanics post-novelty
- Match rate: 1/3 (#3 churn/retention matches BL1 #3 directly and specifically); #1 and #2 are different but plausible absences. Output partially reframes BL1's "FDA pathway" as "international regulatory" — adjacent but not the same gap (BL1 flags US FDA timing as ungrounded; output assumes US FDA addressed and asks about international). BL1 #1 (no consumer-channel for first 10K) is missed entirely — output never questions how the 10,000-unit assumption is reached.
- Specificity: specific (each absence cites concrete artifacts: $9.99/$49 figures, CE/MDR/Health Canada, novelty period)
- Verdict: partial — section is present and specific, but only catches 1/3 BL1 absences and misses the most load-bearing one (no consumer-acquisition channel), which is the structural gap that undermines the entire 10K-unit revenue model the output itself recommends.

## Phase-5 Signal Audit

- **Central Tension** (BL1: clinical-credibility-first vs consumer-business viability during multi-year clinical build): partially preserved in Executive Summary ("the company cannot compete on features against Apple Watch; the only durable position is being more clinically honest") and Risks ("6–12 month sales cycle … cannot rescue a near-term runway problem"). The tension is named but not framed as the cluster's organizing trade-off; reader gets the components without the explicit framing.
- **Recurring-theme tagging:** All 8 action items carry `[recurring]`/`[single]` tags as required by prompt; tags align with BL1 confidence map (10/10 recurring TLs surfaced as `[recurring]` where present; TL-10 and TL-18 correctly tagged `[single]`).
- **Convergence map themes:** Cardiologist-partnership recurrence (BL1's strongest cross-question theme) preserved in 3 places (Action 6, Action 8, Opportunities). Raw-data-never-leaves-device commitment implied but not stated as a recurring architectural constraint.

## Sample Verdict

**Pass:** A AND C. Strict — partial = FAIL.

**Verdict:** FAIL

**Failure modes:**
- Axis A passes (94.4%, recurring 100%) — strong fidelity on through-lines.
- Axis C is **partial, not pass**: section is present, specific, well-formed, but misses 2/3 BL1-identified absences and substitutes adjacent-but-different absences. Most critically, the output flags pricing-sensitivity for the very $9.99/$49 figures it recommends without flagging the upstream gap (no consumer-acquisition channel for the 10,000 units those figures are computed against). The output's absences are reasonable but BL1's are more load-bearing.
- TL-17 dropped: hardware/form-factor recommendation entirely absent, including the load-bearing 20-interview research protocol and the comfort/battery/social-awkwardness abandonment finding. This is the only single-instance hardware-product TL in the cluster.

**Recommended prompt revision target:**
- Strengthen Conspicuous Absences guidance to require the synthesizer to scan the *internal coherence* of its own action recommendations: when a revenue figure assumes a unit volume, flag the absence of any acquisition-channel logic. Generic "what did the brainstormer skip" instruction underweights structural gaps that the synthesis itself replicates.
- Add explicit instruction that hardware/product-design recommendations must surface even when the cluster is GTM-themed; the prompt's emphasis on "patterns" may bias against single-occurrence concrete recommendations like form-factor differentiation.
